RE:ATE.In my opinion Antibe wants to be bought out just by analyzing the deal they made with Knight. See below.
"Under the terms of the license agreement, Antibe has granted Knight the exclusive commercial rights for Antibe’s drug candidates and other future prescription drugs in Canada, Israel, Romania, Russia and sub-Saharan Africa. Antibe is entitled to royalties on annual sales, along with the potential for $10 million in payments for sales-based milestones. Antibe considers this a favourable royalty scenario given its competitive anticipated cost-of-goods structure. The global market for non-steroidal anti-inflammatory and pain drugs is more than US$12 billion annually, despite serious side effects for the currently marketed drugs, especially when taken over the long-term. Antibe’s drug candidates are novel and patent-protected, and are designed to be safer versions of drugs currently on the market.
I think Antibe just wants to sell the company and receive royalties on its products as their end goal.
Knight also gets 500k worth of debentures which it can convert into common shares in October 2018 at $0.22/share from Antibe. It also gets 1,000,000 warrants to buy common shares of Antibe at $0.31/share exercisable until October 15, 2018.